A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

NCT03786419 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Publication of study results of ICI use in MPM as first line therapy

Conditions

Malignant Pleural Mesothelioma, Advanced
Malignant Pleural Mesothelioma, Unresectable

Interventions

DRUG: Atezolizumab

Sponsor

Health Pharma Professional Research